• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Edwards Michael A

    4/3/26 7:10:48 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FRMM alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Edwards Michael A

    (Last)(First)(Middle)
    2875 SOUTH OCEAN BLVD
    SUITE 200

    (Street)
    PALM BEACH FLORIDA 33480

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    FORUM MARKETS Inc [ FRMM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/02/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/02/2026A203,562(1)A$0.00203,562D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Consists of (i) 3,562 shares of Common Stock underlying restricted stock units ("RSUs") that will vest in full on the date of the Company's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service through such date, and (ii) 200,000 shares of Common Stock underlying RSUs, half of which will vest on the date of the Company's 2026 Annual Meeting of Stockholders and the other half of which will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
    /s/ Michael Edwards04/03/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $FRMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRMM

    DatePrice TargetRatingAnalyst
    4/7/2026$5.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $FRMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dalton Angela

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 8:15:10 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dalton Angela

    3 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 7:46:15 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Edwards Michael A

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/3/26 7:10:48 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forum Announces Initiation of Analyst Coverage by Benchmark

    Benchmark Initiates with Speculative Buy Rating and $5.00 Price TargetPALM BEACH, Fla., April 7, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that The Benchmark Company, LLC, a StoneX company, has initiated coverage of Forum's common stock with a Speculative Buy rating and a price target of $5.00 per share. The initiation, published by Benchmark analyst, Mark Palmer, on April 7, 2026, highlights Forum's position as a pure-play early m

    4/7/26 2:43:00 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum to Present at Sidoti's Small-Cap Virtual Investor Conference on March 18

    PALM BEACH, Fla., March 12, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that McAndrew Rudisill, chairman and CEO, and John Kristoff, senior vice president, corporate communications and investor relations, are expected to participate in the Sidoti Small-Cap Virtual Investor Conference on Wednesday, March 18, 2026.  The company will participate in a group presentation at 2:30 PM EDT and will also host virtual one-on-one meeti

    3/12/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    SEC Filings

    View All

    SEC Form EFFECT filed by Forum Markets Incorporated

    EFFECT - FORUM MARKETS Inc (0001690080) (Filer)

    4/10/26 12:15:03 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Markets Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 9:06:39 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Forum Markets Incorporated

    424B3 - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 8:29:06 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Forum Markets with a new price target

    The Benchmark Company initiated coverage of Forum Markets with a rating of Speculative Buy and set a new price target of $5.00

    4/7/26 8:46:27 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Appoints Robert Spake as General Counsel

    PALM BEACH, Fla., March 3, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced the appointment of Robert Spake as the company's general counsel. Spake's deep legal expertise in capital markets, tokenization, and regulatory compliance strengthens Forum's leadership team and sharpens its focus on launching compliant, institutionally structured real-world asset products within evolving regulatory frameworks.  "Robert joins Forum at a pivotal mo

    3/3/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Financials

    Live finance-specific insights

    View All

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care